94 related articles for article (PubMed ID: 16112085)
1. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.
Pinto D; Pereira D; Portela C; da Silva JL; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2005 Oct; 335(4):1173-8. PubMed ID: 16112085
[TBL] [Abstract][Full Text] [Related]
2. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
3. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer.
Duarte I; Santos A; Sousa H; Catarino R; Pinto D; Matos A; Pereira D; Moutinho J; Canedo P; Machado JC; Medeiros R
Biochem Biophys Res Commun; 2005 Aug; 334(2):588-92. PubMed ID: 16009345
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.
Leoutsakou T; Talieri M; Scorilas A
Biochem Biophys Res Commun; 2006 Jun; 344(2):667-74. PubMed ID: 16631123
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
6. A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome.
Wang Y; Wu X; Cao Y; Yi L; Chen J
Fertil Steril; 2006 Jul; 86(1):223-6. PubMed ID: 16764871
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha gene and cerebral aneurysms.
Fontanella M; Rainero I; Gallone S; Rubino E; Fenoglio P; Valfrè W; Garbossa D; Carlino C; Ducati A; Pinessi L
Neurosurgery; 2007 Apr; 60(4):668-72; discussion 672-3. PubMed ID: 17415203
[TBL] [Abstract][Full Text] [Related]
8. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN
Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283
[TBL] [Abstract][Full Text] [Related]
9. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
Serrano-Olvera A; Dueñas-González A; Gallardo-Rincón D; Candelaria M; De la Garza-Salazar J
Cancer Treat Rev; 2006 May; 32(3):180-90. PubMed ID: 16483720
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
13. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
14. Estimating cancer survival and clinical outcome based on genetic tumor progression scores.
Rahnenführer J; Beerenwinkel N; Schulz WA; Hartmann C; von Deimling A; Wullich B; Lengauer T
Bioinformatics; 2005 May; 21(10):2438-46. PubMed ID: 15705654
[TBL] [Abstract][Full Text] [Related]
15. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
16. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
18. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
20. Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
Baba T; Mori S; Matsumura N; Kariya M; Murphy SK; Kondoh E; Kusakari T; Kuroda H; Mandai M; Higuchi T; Takakura K; Fukuda MN; Fujii S
Biochem Biophys Res Commun; 2007 Aug; 360(2):363-9. PubMed ID: 17597582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
